Compare KRYS & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | ICLR |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 9.3B |
| IPO Year | 2017 | 2001 |
| Metric | KRYS | ICLR |
|---|---|---|
| Price | $298.90 | $116.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $297.60 | $178.62 |
| AVG Volume (30 Days) | 273.5K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $38.74 | N/A |
| Revenue Next Year | $32.53 | N/A |
| P/E Ratio | $166.58 | ★ $12.91 |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $123.03 | $66.57 |
| 52 Week High | $319.48 | $211.00 |
| Indicator | KRYS | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 50.50 |
| Support Level | $253.89 | $99.11 |
| Resistance Level | $319.48 | $121.03 |
| Average True Range (ATR) | 11.79 | 6.15 |
| MACD | -0.87 | -0.64 |
| Stochastic Oscillator | 46.86 | 32.51 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.